Tutti i servizi

Pharmaceutical compliance support in India

Regole locali, collegate al vostro modello globale.

Eunomia helps pharmaceutical and biotech teams plan India compliance operations, connecting the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) with advertising law, state-level drug-control processes and practical HCP engagement and review workflows.

Parliamo di questo servizio
Specialisti di compliance discutono i requisiti di mercato: India

Competenza locale · Operatività globale

A chi è rivolto questo supporto

For international pharma teams entering India, emerging biotechs preparing commercial activity and compliance leaders coordinating product, channel and state-level requirements.

La sfida pratica: India

India combines central laws and national marketing-practice requirements with state-level administration of drug manufacture, sale and distribution. Companies also need to operationalise detailed controls for promotional claims, HCP interactions, samples, education programmes and annual marketing-expenditure disclosures.

Dai requisiti all’azione

Come può aiutarvi Eunomia

We can map activities to the applicable national framework, identify state-specific licensing or enforcement questions for local legal review, and translate agreed requirements into SOPs, approval routes, evidence standards and monitoring. Support can include promotional materials review coordination, HCP and event workflows, sample controls, reporting checks, training and automation. India-specific legal advice, licensing work or formal local appointments must be separately scoped with appropriately qualified local professionals; this guide does not claim India-based representation.

Utilizzate la checklist di preparazione alla compliance farmaceutica

Cosa possiamo prendere in carico

Compliance farmaceutica: India: ambito di supporto

01

Interpretazione dei codici locali e gestione delle richieste

02

Revisione delle interazioni con operatori sanitari e associazioni di pazienti

03

Requisiti locali di trasparenza e disclosure

04

Revisione di materiali promozionali e non promozionali

05

Valutazione di compliance per l’ingresso nel mercato

06

Valutazione dei requisiti di competenza e di lingua

Cosa ottenete

Requisiti applicabili (India) integrati nei vostri processi globali

Responsabilità chiare per revisione ed escalation

Supporto locale senza costi fissi superflui

Le regole: India

Cosa determina la compliance: India…

Una breve guida ai principali quadri normativi e di autoregolamentazione. Ogni sintesi rimanda alla relativa fonte ufficiale qui sotto.

UCPMP 2024 is a mandatory national code

The Department of Pharmaceuticals describes UCPMP 2024 as mandatory. It establishes ethical standards for pharmaceutical promotion and industry interactions with healthcare practitioners. Complaints are handled through association-level Ethics Committees for Pharma Marketing Practices, with an appeal mechanism at the Department of Pharmaceuticals. The Code is a distinct compliance layer alongside statutory requirements.

Promotion must follow marketing approval and support its claims

UCPMP says a drug must not be promoted before competent-authority marketing approval and that promotion must remain consistent with that approval. Claims should be current, balanced, verifiable and capable of substantiation. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 separately prohibits misleading drug advertisements and advertisements for specified diseases and conditions. Review intended audience, content and channel against the product approval and applicable law.

HCP benefits and hospitality have strict limits

UCPMP prohibits gifts or personal benefits for healthcare practitioners and their family members, as well as pecuniary advantage or benefits in kind to people qualified to prescribe or supply drugs. It also restricts company-funded travel and hospitality, with limited Code conditions for speakers at CME/CPD programmes; monetary grants to HCPs or family members are prohibited. Build documented purpose, approvals, contracts, event controls and escalation into engagement workflows.

CME, CPD and event support need transparent controls

The Code requires well-defined, transparent and verifiable guidelines for industry engagement in CME/CPD and related events. It prohibits events in foreign locations, identifies eligible organiser categories, and requires companies to publish event and expenditure details on their websites. Organisers must disclose participant and speaker selection procedures, funding sources and expenditure; the Code also sets a 1:10 speaker-to-participant ratio for covered in-country events. Confirm the exact event model, organiser and applicable provisions before committing support.

Samples require eligibility, quantity and value controls

Samples may be supplied only to people qualified to prescribe the product, for awareness and experience, and must be recorded and controlled. UCPMP limits sample packs to the prescribed course for no more than three patients and no more than 12 packs per drug per practitioner each year; packs must be marked not for sale and cannot exceed the smallest market pack. The total monetary value of samples should not exceed 2% of domestic sales. The 2025 amendment clarifies sample valuation for annual reporting.

Annual expenditure reporting and state administration

Under the UCPMP text updated on 1 September 2025, the executive head submits an annual marketing-expenditure disclosure within two months after the financial year, through a member association or the Department of Pharmaceuticals portal where the company is not an association member. The prescribed form captures domestic sales, sample value and HCP recipient counts, and education-programme expenditure and event counts. Separately, CDSCO says states primarily regulate manufacture, sale and distribution of drugs, while central authorities handle functions including new-drug approvals, standards and import quality. Map the state footprint and applicable licensing or enforcement touchpoints.

Domande e risposte

Compliance farmaceutica: India: domande frequenti

Is UCPMP 2024 voluntary or mandatory?

The Department of Pharmaceuticals' UCPMP portal describes the 2024 Code as mandatory. It operates alongside applicable statutes and is implemented through pharmaceutical association ethics committees and a Department-level appeal mechanism.

Can a company promote a medicine before it is approved in India?

No. UCPMP says promotion must not begin before the competent authority has granted marketing approval and must remain consistent with that approval.

Can pharmaceutical companies provide gifts or pay for HCP travel?

UCPMP prohibits gifts, personal benefits and monetary grants to HCPs and their family members, and restricts travel and hospitality. The Code contains limited conditions for speakers at CME/CPD programmes, so each arrangement needs review against the full provision.

What UCPMP transparency reporting applies?

The updated Code requires an annual marketing-expenditure disclosure. Its prescribed form includes domestic sales, sample value and HCP recipient counts, and expenditure and event counts for education programmes. The submission route depends on association membership; check the current Department form and any deadline extensions.

Do state-level requirements matter if UCPMP is national?

Yes. UCPMP and central laws form part of the national framework, while CDSCO says states primarily regulate drug manufacture, sale and distribution. Companies should map state licensing and enforcement touchpoints to their operating footprint.

Does Eunomia have an India office or named India-based representative?

This guide does not claim an India office, India-based representative, legal qualification or formal regulatory appointment. Contact Eunomia to agree the scope, expertise and delivery arrangements required; any local legal advice or formal role must be separately confirmed.

Raccontateci cosa avete sulla scrivania.

Vi ascolteremo, faremo qualche domanda e consiglieremo l’ambito più adatto, senza impegno né pressioni.

Avviate una conversazione